Dihydralazine

Summary

Dihydralazine (CHEMBL35505) is a phase-3 clinical-stage small molecule (ATC C02DB01); indicated across 2 conditions including hypertensive disorder and aortic valve stenosis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: C02DB01
• Indications: 2 conditions
• Clinical trials: 2
• Chemistry: 190.21 Da · C8H10N6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL35505
Name	Dihydralazine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	10230
ATC	C02DB01
Molecular formula	C8H10N6
Molecular weight	190.21
InChIKey	VQKLRVZQQYVIJW-UHFFFAOYSA-N

SMILES: C1=CC=C2C(=C1)C(=NN=C2NN)NN

IUPAC name: (4-hydrazinylphthalazin-1-yl)hydrazine

Also known as: Dihidralazina, Dihydralazine, NSC-526654, SID29215360, DIHYDRALAZINE, SID144205206, SID170466387, DIHYDRALAZINE MESYLATE, dihydralazine

Parent form; salt/anhydrous children: CHEMBL2106266

Patent coverage: 831 distinct patent families (2,560 SureChEMBL compound mentions), from 5 matched compound structure(s). One matched structure accounts for 2,452 (96%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 10 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Microtubule-associated protein tau, Fructose-bisphosphate aldolase, 4’-phosphopantetheinyl transferase ffp, Amine oxidase [flavin-containing] A, Prostaglandin G/H synthase 1, Mu-type opioid receptor, Voltage-gated inwardly rectifying potassium channel KCNH2, Adenosine receptor A3, Aldehyde dehydrogenase 1A1.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 12 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ADORA3	6.71	AC50	197.1	nM	CHEMBL_ACT_25199098
PTGS1	6.46	AC50	344.4	nM	CHEMBL_ACT_25205703
KCNH2	6.36	AC50	440	nM	CHEMBL_ACT_25118579
PTGS1	6.36	AC50	433.8	nM	CHEMBL_ACT_25206633

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hypertensive disorder	3	MONDO:0005044	EFO:0000537
aortic valve stenosis	3	MONDO:0042981	EFO:0000266

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE4	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00311974	PHASE4	COMPLETED	The Effect of Dihydralazine on Kidney Function and Hormones in Healthy Individuals
NCT05230901	PHASE3	UNKNOWN	Effect of Antifibrotic Therapy on Regression of Myocardial Fibrosis After Transcatheter Aortic Valve Implantation (TAVI) in Aortic Stenosis Patients With High Fibrotic Burden

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).